Generic drug
Metformin / pioglitazone price, strengths & recalls
Pharmacies pay $8.82 for 30 tablets of Metformin / pioglitazone 500 mg / 15 mg tablet this week, and from $6.25 to $8.82 across its 2 priced strengths and forms. 4 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on September 11, 2026.
Generic- Fair cash price
- $20.64
- Strengths
- 2
- Makers
- 4
- Updated
- Nov 11
Metformin / pioglitazone price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 500 mg / 15 mg tablet | $0.2940 | $8.82 / 30 tablets |
| 850 mg / 15 mg tablet | $0.2083 | $6.25 / 30 tablets |
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Metformin / pioglitazone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use PIOGLITAZONE AND METFORMIN HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE AND METFORMIN HYDROCHLORIDE TABLETS. PIOGLITAZONE and METFORMIN HYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 2005
WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS
Congestive Heart Failure
Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1)].
After initiation of pioglitazone and metformin hydrochloride, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If congestive heart failure develops while taking pioglitazone and metformin hydrochloride, consider discontinuation of pioglitazone and metformin hydrochloride or dosage reduction of pioglitazone in pioglitazone and metformin hydrochloride [see Warnings and Precautions (5.1)].
Pioglitazone and metformin hydrochloride is not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1)].
Initiation of pioglitazone and metformin hydrochloride in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4), Warnings and Precautions (5.1)].
Lactic Acidosis
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmia's. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL [see Warnings and Precautions (5.2)].
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.2)].
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.2), Drug Interactions (7), Use in Specific Populations (8.6, 8.7)].
If metformin-associated lactic acidosis is suspected, immediately discontinue pioglitazone and metformin hydrochloride and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.2)].
WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS
See full prescribing information for complete boxed warning.
Congestive Heart Failure
Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride, cause or exacerbate congestive heart failure in some patients. (5.1)
After initiation of pioglitazone and metformin hydrochloride, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If congestive heart failure develops while taking pioglitazone and metformin hydrochloride, consider discontinuation of pioglitazone and metformin hydrochloride or dosage reduction of pioglitazone in pioglitazone and metformin hydrochloride. (5.1)
Pioglitazone and metformin hydrochloride is not recommended in patients with symptomatic heart failure. (5.1)
Initiation of pioglitazone and metformin hydrochloride in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated. (4, 5.1)
Lactic Acidosis
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmia's. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL. (5.2)
Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information. (5.2)
If lactic acidosis is suspected, discontinue pioglitazone and metformin hydrochloride and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.2)
Recent major changes (as listed on the label)
Boxed Warning 08/2026
Warnings and Precautions, Lactic Acidosis (5.2) 08/2026
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 2 approved generic applications on the market
Metformin / pioglitazone questions
How much does metformin / pioglitazone cost without insurance?
Pharmacies pay about $8.82 for 30 tablets of metformin / pioglitazone 500 mg / 15 mg tablet ($0.2940 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $20.64. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is metformin / pioglitazone in shortage?
No shortage is reported for metformin / pioglitazone right now. We check the national shortage list every day.
Has metformin / pioglitazone been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the metformin / pioglitazone label last change?
The official label was last updated on September 11, 2026 (version 15). See what changed.
Talk about metformin / pioglitazone
No comments yet. Questions, tips, what worked for you - start the conversation.